{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:13:26Z","timestamp":1793726006741,"version":"4.6.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015663","name":"Friends of the Cancer Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001626","name":"Public Health Agency Northern Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001626","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ijrobp.2023.02.054","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T01:56:23Z","timestamp":1678240583000},"page":"594-609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A Randomized Feasibility Trial of Stereotactic Prostate Radiation Therapy With or Without Elective Nodal Irradiation in High-Risk Localized Prostate Cancer (SPORT Trial)"],"prefix":"10.1016","volume":"117","author":[{"given":"Orla A.","family":"Houlihan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran","family":"Fairmichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara A.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor K.","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Prise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R.","family":"Hounsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe M.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneil","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.02.054_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0002","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0003","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized phase III trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0004","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0005","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0006","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ijrobp.2008.10.091","article-title":"Higher-than-conventional radiation doses in localized prostate cancer treatment: A meta-analysis of randomized, controlled trials","volume":"74","author":"Viani","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0007","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of conventional-dose versus high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0008","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0009","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ijrobp.2006.05.074","article-title":"Whole-pelvis, \u201cmini-pelvis,\u201d or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial","volume":"66","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0010","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2003.05.004","article-title":"Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413","volume":"21","author":"Roach","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0011","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","article-title":"An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone\/radiation interactions","volume":"69","author":"Lawton","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0012","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2\u00a0=\u00a01.4 (0.9-2.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0013","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","article-title":"Meta-analysis of the alpha\/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or no news?","volume":"85","author":"Vogelius","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 suppl","key":"10.1016\/j.ijrobp.2023.02.054_bib0014","doi-asserted-by":"crossref","first-page":"e31s","DOI":"10.1200\/JOP.2012.000548","article-title":"Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: An emerging initial radiation treatment option for organ-confined prostate cancer","volume":"8","author":"Hodges","year":"2012","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0015","first-page":"12","article-title":"Stereotactic ablative radiotherapy: Aim for a cure of cancer","volume":"3","author":"Chang","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0016","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1016\/j.ijrobp.2011.11.030","article-title":"Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study","volume":"82","author":"Arrayeh","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0017","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.clon.2015.06.015","article-title":"Functional radiotherapy targeting using focused dose escalation","volume":"27","author":"Alonzi","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0018","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13014-014-0275-6","article-title":"Hypofractionated radiotherapy for prostate cancer","volume":"9","author":"Hegemann","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0019","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clgc.2015.12.005","article-title":"Radiotherapy boost for the dominant intraprostatic cancer lesion-a systematic review and meta-analysis","volume":"14","author":"von Eyben","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fonc.2017.00005","article-title":"Intensity-modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: A report on 3-year toxicity","volume":"7","author":"Paydar","year":"2017","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0021","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13014-016-0585-y","article-title":"Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer","volume":"11","author":"Anwar","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0022","doi-asserted-by":"crossref","first-page":"662","DOI":"10.4161\/cc.9.4.10764","article-title":"\u03b3H2AX foci analysis for monitoring DNA double-strand break repair: Strengths, limitations and optimization","volume":"9","author":"L\u00f6brich","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0023","doi-asserted-by":"crossref","first-page":"e79541","DOI":"10.1371\/journal.pone.0079541","article-title":"Use of the \u03b3-H2AX assay to investigate DNA repair dynamics following multiple radiation exposures","volume":"8","author":"Mariotti","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0024","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3390\/cancers12092517","article-title":"Monitoring DNA damage and repair in peripheral blood mononuclear cells of lung cancer radiotherapy patients","volume":"12","author":"Lobachevsky","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0025","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-16-0138","article-title":"Radiotherapy for non-small cell lung cancer induces DNA damage response in both irradiated and out-of-field normal tissues","volume":"22","author":"Siva","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0026","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/fon.15.334","article-title":"Prediction of radiation-induced toxicity by in vitro radiosensitivity of lymphocytes in prostate cancer patients","volume":"12","author":"Pinkawa","year":"2016","journal-title":"Future Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0027","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13014-017-0792-1","article-title":"Prostate cancer treated with brachytherapy; an exploratory study of dose-dependent biomarkers and quality of life","volume":"12","author":"Osman","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0028","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/2050640617737632","article-title":"Citrulline as a marker of intestinal function and absorption in clinical settings: A systematic review and meta-analysis","volume":"6","author":"Fragkos","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0029","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2004.02.052","article-title":"Plasma citrulline concentration: A surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients","volume":"60","author":"Lutgens","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0030","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3109\/0284186X.2011.584557","article-title":"Plasma citrulline levels predict intestinal toxicity in patients treated with pelvic radiotherapy","volume":"50","author":"Onal","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0031","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0032","first-page":"22","article-title":"PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0033","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0034","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0035","unstructured":"R Core Team. R: A language and environment for statistical computing. Available at: https:\/\/www.R-project.org\/. Accessed November 7, 2022."},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0036","unstructured":"Therneau T. A package for survival analysis in R. R package version 3.4-0. Available at: https:\/\/CRAN.R-project.org\/package=survival. Accessed November 7, 2022."},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0037","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijrobp.2018.11.011","article-title":"SABR in high-risk prostate cancer: Outcomes from 2 prospective clinical trials with and without elective nodal irradiation","volume":"104","author":"Alayed","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0038","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase 1-2 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): Early toxicity and quality of life","volume":"102","author":"Musunuru","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0039","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.ijrobp.2015.02.046","article-title":"A phase 1\/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer","volume":"92","author":"Bauman","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0040","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.adro.2019.07.007","article-title":"A phase I\/II trial of fairly brief androgen suppression and stereotactic radiation therapy for high-risk prostate cancer (FASTR-2): Preliminary results and toxicity analysis","volume":"4","author":"Callan","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0041","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijrobp.2021.10.137","article-title":"SABR for high-risk prostate cancer\u2014A prospective multilevel MRI-based dose escalation trial","volume":"113","author":"Hannan","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0042","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2022.05.050","article-title":"Acute and late toxicity of prostate-only or pelvic SBRT in prostate cancer: a comparative study","volume":"114","author":"Murthy","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0043","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0360-3016(97)00926-7","article-title":"Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma","volume":"40","author":"Asbell","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0044","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1200\/JCO.2006.10.5171","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01","volume":"25","author":"Pommier","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2019.03.022","article-title":"Prostate-only versus whole-pelvis radiation with or without a brachytherapy boost for Gleason grade group 5 prostate cancer: A retrospective analysis","volume":"77","author":"Sandler","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0046","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): Long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0047","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0048","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","article-title":"Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial","volume":"145","author":"Murthy","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.02.054_bib0049","unstructured":"ClinicalTrials.gov. Androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01368588. Accessed May 14, 2022."}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623002171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623002171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:10:07Z","timestamp":1759745407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623002171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0360301623002171"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.02.054","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Feasibility Trial of Stereotactic Prostate Radiation Therapy With or Without Elective Nodal Irradiation in High-Risk Localized Prostate Cancer (SPORT Trial)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.02.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}